Merck Invests $125M in Moderna in Expanded mRNA Cancer Vaccine Partnership

Merck & Co. will invest $125 million in Moderna Therapeutics’ upcoming Series H equity round, the companies said, in an expansion of their two-year-old collaboration to develop and commercialize novel mRNA-based personalized cancer vaccines.The expansion will now include partnering on mRNA-5671, Moderna’s mRNA KRAS cancer vaccine, and other shared antigen mRNA cancer vaccines. mRNA-5671 is a cancer vaccine designed to encode for KRAS epitopes. The vaccine includes an mRNA that en